Exosome-based therapeutics
for regenerative medicine
Unlocking the exosome revolution across
multiple disease indications
Building a pipeline through scalable
and reproducible exosome biology
clinical development
production yield in a tenth of the time
EVerZom mission:
Turning exosome science into therapies
The challenge
Exosomes are natural cell-derived vesicles with immunomodulatory and regenerative properties. To accelerate clinical translation and therapeutic diffusion, one challenge need to be adress: the manufacturing.
EVerZom technology
EVerZom combines proprietary manufacturing and formulation technologies designed for scalable, reproducible, and clinical-grade exosome therapeutics.
EverGel
EverGel is our lead therapeutic candidate advancing toward clinical development for fistula healing in Crohn’s disease. We are expanding our technology across other regenerative applications.
Pipeline
EVerGel
Naïve exosomes + thermoresponsive hydrogel for digestive tissue healing
EViv
Naïve exosomes intravenous for organ regeneration
Investors
With a differentiated technology platform and a clear path to industrialization, EVerZom is positioned to help shape the future of regenerative medicine. Learn more about our strategy, progress, and investment opportunity.
